Advertisement
A or BDX or COO
Which Stock Would AI Choose? Agilent Technologies (A) vs. Becton, Dickinson and Company (BDX) vs. The Cooper Companies (COO) Stock Comparison
Key Takeaways
- Agilent Technologies (A) delivered a strong fiscal Q2 2026 earnings beat with 6.3% core revenue growth and raised full-year guidance, triggering a sharp stock rally in recent market activity.
- Becton, Dickinson and Company (BDX) reported solid Q2 results with 5.2% reported revenue growth and raised adjusted earnings per share guidance while executing share repurchases and debt reduction.
- The Cooper Companies (COO) has faced recent stock pressure, trading near 52-week lows ahead of its upcoming Q2 2026 earnings release, with focus on contact lens and surgical segment demand.
- All three companies operate in healthcare and life sciences, with A emphasizing analytical instruments, BDX medical devices and diagnostics, and COO vision and surgical products.
- Recent performance shows divergence: A exhibited strong momentum post-earnings, while BDX maintained stability and COO experienced valuation compression amid sector headwinds.
- Market sentiment reflects earnings catalysts for A and BDX versus pre-earnings caution for COO in the current environment.
Introduction
This comparison examines Agilent Technologies (A), Becton, Dickinson and Company (BDX), and The Cooper Companies (COO) to highlight differences in business models, recent performance, and market positioning within the healthcare and life sciences sectors. These stocks appeal to investors and traders seeking exposure to medical technology, diagnostics, and analytical tools amid evolving demand patterns. The analysis focuses on observable factors such as earnings results, revenue trends, and relative stock behavior over recent weeks to provide a factual basis for evaluating their profiles. Readers interested in sector-specific dynamics or diversified healthcare allocations may find the relative performance insights relevant for portfolio context.
A Overview and Recent Performance
Agilent Technologies (A) provides analytical and clinical laboratory instruments serving life sciences, chemical, and industrial markets. In recent market activity, the company reported fiscal second-quarter 2026 results that exceeded expectations across revenue and earnings metrics. Core revenue grew 6.3% year-over-year to $1.83 billion, supported by pharmaceutical and biotech demand. Non-GAAP earnings per share reached $1.49, reflecting 14% growth, prompting an upward revision to full-year fiscal 2026 guidance. The stock responded with notable gains following the announcement, reflecting improved sentiment tied to broad-based end-market strength and operational execution.
BDX Overview and Recent Performance
Becton, Dickinson and Company (BDX) develops medical devices, diagnostics, and interventional solutions. The company reported fiscal second-quarter 2026 results in early May, showing reported revenue of $4.714 billion, up 5.2%, or 2.6% on a foreign exchange-neutral basis. Adjusted diluted earnings per share of $2.90 surpassed consensus estimates, leading to raised full-year adjusted earnings guidance. Management also completed a significant share repurchase program and debt retirement. Recent trading has reflected steady positioning around current levels, with dividend declarations supporting shareholder returns amid ongoing sector dynamics.
COO Overview and Recent Performance
The Cooper Companies (COO) focuses on contact lenses through CooperVision and surgical and fertility products via CooperSurgical. Recent market activity has shown stock price pressure, with shares trading near 52-week lows ahead of the scheduled fiscal second-quarter 2026 earnings release on June 4. Earlier in the year, the company raised full-year revenue guidance, citing organic growth expectations in premium segments. Performance has been influenced by demand patterns in vision care and surgical offerings, with share repurchases continuing as part of capital allocation. Sentiment remains tempered pending further updates on execution.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of high-performing AI trading bots from a broader library of hundreds available across thousands of tickers. Only those demonstrating the strongest suitability for prevailing market conditions are featured in this section. Bots in the platform exhibit varied trading styles, strategies, timeframes, performance statistics, and ticker coverage, allowing users to explore options aligned with specific objectives. Available data includes ranges of historical win rates, average returns, and drawdown metrics that provide context on bot characteristics. Review the Trending AI Robots page for detailed listings and performance information.
Head-to-Head Comparison
Agilent Technologies (A), Becton, Dickinson and Company (BDX), and The Cooper Companies (COO) differ in scale, end-market exposure, and growth drivers. A centers on precision instruments with sensitivity to research and pharmaceutical spending, recently benefiting from broad demand strength. BDX offers a diversified medical device portfolio with recurring revenue elements and has pursued balance sheet optimization through repurchases and debt management. COO concentrates on consumer-facing vision products and procedural offerings, facing nearer-term visibility tied to upcoming results amid prior valuation compression. Relative momentum favors A following its earnings catalyst, while BDX shows operational consistency and COO contends with pre-earnings positioning. Valuation sensitivity varies, with healthcare sector factors influencing all three amid broader economic considerations.
Tickeron AI Verdict
Based on observable trend consistency, earnings delivery, and relative positioning in recent activity, Tickeron’s AI would currently assign a probabilistic preference toward Agilent Technologies (A) among the three. Factors include the magnitude of the recent earnings beat, guidance uplift, and associated price response, which contrast with BDX’s steady but less dynamic profile and COO’s pending catalysts. This assessment reflects data-driven pattern recognition rather than forward projections and remains subject to evolving market inputs.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileBDX’s FA Score has 1 green FA rating(s), and COO’s FA Score reflects 1 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- BDX’s FA Score: 1 green, 4 red.
- COO’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while BDX’s TA Score has 2 bullish TA indicator(s), and COO’s TA Score reflects 5 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 5 bearish.
- BDX’s TA Score: 2 bullish, 7 bearish.
- COO’s TA Score: 5 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а -3.14% price change this week, while BDX (@Pharmaceuticals: Other) price change was -3.31% , and COO (@Pharmaceuticals: Other) price fluctuated -3.45% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.45%. For the same industry, the average monthly price growth was +2.48%, and the average quarterly price growth was -3.19%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -2.31%. For the same industry, the average monthly price growth was -0.98%, and the average quarterly price growth was -14.76%.
Reported Earning Dates
A is expected to report earnings on Aug 18, 2026.
BDX is expected to report earnings on Jul 30, 2026.
COO is expected to report earnings on Sep 02, 2026.
Industries' Descriptions
@Medical Specialties (+0.45% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Pharmaceuticals: Other (-2.31% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| A | BDX | COO | |
| Capitalization | 35.7B | 38.8B | 12.8B |
| EBITDA | 1.96B | 4.97B | 1.08B |
| Gain YTD | -6.662 | -6.559 | -20.181 |
| P/E Ratio | 25.40 | 24.56 | 55.44 |
| Revenue | 7.23B | 22.2B | 4.15B |
| Total Cash | 1.81B | N/A | 125M |
| Total Debt | 3.36B | 17.3B | 2.5B |
A | BDX | COO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 91 | 63 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 5 Undervalued | 72 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 100 | |
SMR RATING 1..100 | 44 | 87 | 86 | |
PRICE GROWTH RATING 1..100 | 47 | 58 | 59 | |
P/E GROWTH RATING 1..100 | 62 | 76 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 50 | 46 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BDX's Valuation (5) in the Medical Specialties industry is in the same range as A (6) in the Biotechnology industry, and is significantly better than the same rating for COO (72) in the Medical Specialties industry. This means that BDX's stock grew similarly to A’s and significantly faster than COO’s over the last 12 months.
BDX's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as A (100) in the Biotechnology industry, and is in the same range as COO (100) in the Medical Specialties industry. This means that BDX's stock grew similarly to A’s and similarly to COO’s over the last 12 months.
A's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for COO (86) in the Medical Specialties industry, and is somewhat better than the same rating for BDX (87) in the Medical Specialties industry. This means that A's stock grew somewhat faster than COO’s and somewhat faster than BDX’s over the last 12 months.
A's Price Growth Rating (47) in the Biotechnology industry is in the same range as BDX (58) in the Medical Specialties industry, and is in the same range as COO (59) in the Medical Specialties industry. This means that A's stock grew similarly to BDX’s and similarly to COO’s over the last 12 months.
COO's P/E Growth Rating (14) in the Medical Specialties industry is somewhat better than the same rating for A (62) in the Biotechnology industry, and is somewhat better than the same rating for BDX (76) in the Medical Specialties industry. This means that COO's stock grew somewhat faster than A’s and somewhat faster than BDX’s over the last 12 months.
| A | BDX | COO | |
|---|---|---|---|
| RSI ODDS (%) | 2 days ago 76% | N/A | 2 days ago 60% |
| Stochastic ODDS (%) | 2 days ago 56% | 2 days ago 54% | 2 days ago 55% |
| Momentum ODDS (%) | 2 days ago 60% | 2 days ago 46% | 2 days ago 62% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 41% | N/A |
| TrendWeek ODDS (%) | 2 days ago 64% | 2 days ago 44% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 58% | 2 days ago 44% | 2 days ago 49% |
| Advances ODDS (%) | 9 days ago 60% | 19 days ago 43% | 19 days ago 57% |
| Declines ODDS (%) | 7 days ago 62% | 8 days ago 43% | 8 days ago 60% |
| BollingerBands ODDS (%) | 2 days ago 52% | 2 days ago 52% | 2 days ago 65% |
| Aroon ODDS (%) | 2 days ago 67% | 2 days ago 36% | 2 days ago 50% |
Advertisement
BDX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BDX has been loosely correlated with COO. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BDX jumps, then COO could also see price increases.
| Ticker / NAME | Correlation To BDX | 1D Price Change % | ||
|---|---|---|---|---|
| BDX | 100% | -2.27% | ||
| COO - BDX | 53% Loosely correlated | -0.74% | ||
| TMO - BDX | 50% Loosely correlated | -0.13% | ||
| CNMD - BDX | 48% Loosely correlated | -0.12% | ||
| BAX - BDX | 46% Loosely correlated | -1.16% | ||
| RVTY - BDX | 45% Loosely correlated | -0.96% | ||
More | ||||
COO and
Correlation & Price change
A.I.dvisor indicates that over the last year, COO has been loosely correlated with BDX. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if COO jumps, then BDX could also see price increases.